References

 

  1. Evgenia K, Salgado C, Banks A, et al. Peripherally inserted central catheter-associated bloodstream infection: Risk factors and the role of antibiotic-impregnated catheters for prevention. Am J Infect Control. 2018;S0196-6553(18):30749-30751. https://www.ajicjournal.org/article/S0196-6553(18)30749-1/fulltext
  2. Kramer RD, Rogers MA, Conte M, et al. Are antimicrobial peripherally inserted central catheters associated with reduction in central line-associated bloodstream infection? A systematic review and meta-analysis. Am J Infect Control. 2017;45(2):108-114. https://www.ncbi.nlm.nih.gov/pubmed/28341283
  3. Bonne S, Mazuski JE, Sona C, et al. Effectiveness of minocycline and rifampin vs chlorhexidine and silver sulfadiazine-impregnated central venous catheters in preventing central line-associated bloodstream infection in a high-volume academic intensive care unit: a before and after trial. Journal of the American College of Surgeons. 2015;221(3):739-747. https://www.ncbi.nlm.nih.gov/pubmed/26199017
  4. Baskin KM, Hunnicutt C, Beck ME, et al. Long-term central venous access in Pediatric patients at high risk: Conventional versus antibiotic-impregnated catheters. Vasc Interv Radiol. 2014;25(3):411-418. http://dx.doi.org/10.1016/j.jvir.2013.11.024
  5. Chaftari A, Kassis C, El Issa H, et al. Novel approach using antimicrobial catheters to improve the management of central line-associated bloodstream infections in cancer patients. Cancer. 2011;117(11):2551-2558. http://onlinelibrary.wiley.com/doi/10.1002/cncr.25807/full
  6. Hockenhull JC, Dwan KM, Smith GW, et al. The clinical effectiveness of central venous catheters treated with anti-infective agents in preventing catheter-related bloodstream infections: a systematic review. Crit Care Med. 2009;37(2):702-712. ncbi.nlm.nih.gov/pubmed/19114884
  7. Ramritu P, Halton K, Collignon P, et al. A systematic review comparing the relative effectiveness of antimicrobial-coated catheters in intensive care units.Am J Infect Control. 2008;36(2):104-117. ncbi.nlm.nih.gov/pubmed/18313512
  8. Casey AL, Mermel LA, Nightingale P, et al. Antimicrobial central venous catheters in adults: a systematic review and meta-analysis. Lancet Infect Dis. 2008;8(12):763-776. ncbi.nlm.nih.gov/pubmed/19022192
  9. Gilbert RE, Harden M. Effectiveness of impregnated central venous catheters for catheter related blood stream infection: a systematic review. Curr Opin Infect Dis. 2008;21(3):235-245. ncbi.nlm.nih.gov/pubmed/18448967
  10. Schuerer DJ, Zack JE, Thomas J, et al. Effect of chlorhexidine/silver sulfadiazine-impregnated central venous catheters in an intensive care unit with a low blood stream infection rate after implementation of an educational program: a before-after trial. Surgical Infections. 2007;8(4):445-454. ncbi.nlm.nih.gov/pubmed/17883361
  11. Falagas ME, Fragoulis K, Bliziotis IA, et al. Rifampicin-impregnated central venous catheters: a meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2007;59(3):359-369. jac.oxfordjournals.org/content/59/3/359.full
  12. Hanna H, Bahna P, Reitzel R, et al. Comparative in vitro efficacies and antimicrobial durabilities of novel antimicrobial central venous catheters. Antimicrob Agents Chemother.2006;50(10):3283-3288. ncbi.nlm.nih.gov/pmc/articles/PMC1610097
  13. Still J, Law E, Friedman B, et al.Vancomycin-resistant organisms on a burn unit. Southern Medical Journal. 2001;94(8):810-812. ncbi.nlm.nih.gov/pubmed/11549193
  14. Darouiche RO, Raad II, Heard SO, et al. A comparison of two antimicrobial-impregnated central venous catheters. N Engl J Med. 1999;340(1):1-8. nejm.org/doi/full/10.1056/NEJM199901073400101
  15. Wenzel RP, Edmund MB. The evolving technology of venous access. N Engl J Med. 1999;340(1):48-50. ncbi.nlm.nih.gov/pubmed/9878645
  16. Marik PE, Abraham G, Careau P, et al. The ex vivo antimicrobial activity and colonization rate of two antimicrobial-bonded central venous catheters. Crit Care Med. 1999;27(6):1128-1131. ncbi.nlm.nih.gov/pubmed/10397217
  17. Raad I, Darouiche RO, Hachem R, et al. Antimicrobial durability and rare ultrastructural colonization of indwelling central catheters coated with minocycline and rifampin. Crit Care Med. 1998;26(2):219-224. ncbi.nlm.nih.gov/pubmed/9468157
  18. Raad I, Darouiche R, Dupuis J, et al. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. Ann Intern Med. 1997;127(4):267-274. annals.org/article.aspx?articleid=710759
  19. Raad I, Reitzel R, Jiang Y, et al. Anti-adherence activity and antimicrobial durability of anti-infective-coated catheters against multidrug-resistant bacteria. J Antimicrob Chemother. 2008;62(4):746-750. jac.oxfordjournals.org/content/62/4/746
  20. Raad I, Darouiche R, Hachem R, et al. The broad-spectrum activity and efficacy of catheters coated with minocycline and rifampin. J Infect Dis. 1996;173(2):418-424. jstor.org/stable/30126138
  21. Raad I, Darouiche R, Hachem R, et al. Antibiotics and prevention of microbial colonization of catheters. Antimicrob Agents Chemother. 1995;39(11):2397-2400. ncbi.nlm.nih.gov/pmc/articles/PMC162954
  22. Darouiche RO, Raad II, Bodey GP, et al. Antibiotic susceptibility of staphylococcal isolates from patients with vascular catheter-related bacteremia: potential role of the combination of minocycline and rifampin. Int J Antimicrob Agents. 1995;6(1):31-36. ncbi.nlm.nih.gov/pubmed/18611682
  23. Warren DK, Quadir WW, Hollenbeak CS, et al. Attributable cost of catheter-associated bloodstream infections among intensive care patients in a nonteaching hospital. Crit Care Med. 2006;34(8):2084-2089. ncbi.nlm.nih.gov/pubmed/16763511
  24. Cosgrove SE. Evidence that prevention makes cents: costs of catheter-associated bloodstream infections in the intensive care unit. Crit Care Med. 2006;34(8):2243-2244. ncbi.nlm.nih.gov/pubmed/16883193
  25. Hanna HA, Raad II, Hackett B, et al. Antibiotic-impregnated catheters associated with significant
    decrease in nosocomial and multidrug-resistant bacteremias in
    critically ill patients. Chest. 2003;124(3):1030-1038. ncbi.nlm.nih.gov/pubmed/12970034
  26. Shorr AF, Humphreys CW, Helman DL.
    New choices for central venous catheters: potential financial implications. Chest. 2003;124(1):275-284. ncbi.nlm.nih.gov/pubmed/12853534
  27. Marciante KD, Veenstra DL, Lipsky BA, et al. Which antimicrobial impregnated central venous catheter should we use? Modeling the costs and outcomes of antimicrobial catheter use. Am J Infect Control. 2003;31(1):1-8. ncbi.nlm.nih.gov/pubmed/12548250
  28. Shojania KG, Duncan BW, McDonald KM, et al. Making health care safer: a critical analysis of patient safety practices. Evid Rep Technol Assess (Sum). 2001;(43):1-12. ncbi.nlm.nih.gov/pubmed/11510252
  29. Turnbull IR, Buckman SA, Horn CB, et al. Antibiotic-impregnated central venous catheters do not change antibiotic resistance patterns. Surg Infect (Larchmt). 2018;19(1):40–47. ncbi.nlm.nih.gov/pubmed/29028461
  30. Ramos ER, Reitzel R, Jiang Y, et al. Clinical effectiveness and risk of emerging resistance associated with prolonged use of antibiotic-impregnated catheters: more than 0.5 million catheter days and 7 years of clinical experience. Crit Care Med. 2011;39(2):245-251. ncbi.nlm.nih.gov/pubmed/21057308
  31. Chatzinikolaou I, Hanna H, Graviss L, et al. Clinical experience with minocycline and rifampin-impregnated central venous catheters in bone marrow transplantation recipients: efficacy and low risk of developing staphylococcal resistance. Infect Control Hosp Epidemiol. 2003;24(12):961-963. ncbi.nlm.nih.gov/pubmed/14700414
  32. Crnich CJ, Maki DG.
    New technology for reducing infection and resistance in the ICU. J Crit Illn. 2002;17;48-51. business.highbeam.com/4312/article-1G1-83373440/new-technology-reducing-infection-and-resistance-icu
  33. Brooks K, Dauenhauer S, Nelson M. Comparison of an untreated vs. silver/chlorhexidine vs. rifampin/minocycline central venous catheter in reducing catheter-related bloodstream infections. Abstract presented at: APIC 28th Annual Educational Conference and International Meeting; June 10-14, 2001; Seattle, WA.
  34. Friedman BC, Mohammad AHM, Mullins RF, et al. Five-lumen antibiotic-impregnated femoral central venous catheters in severely burned patients: an investigation of device utility and catheter-related bloodstream infection rates. J Burn Care Res. 2015;36(4):493-499. https://www.ncbi.nlm.nih.gov/pubmed/25407386
  35. Armstrong D, Thomas W, Neaman KC, et al. The impact of antibiotic impregnated PICC lines on the incidence of bacteria in a regional burn center. Burns. 2013;39(4):632-635. http://www.sciencedirect.com/science/article/pii/S0305417912002811
  36. Weber JM, Sheridan RL, Fagan S, et al. Incidence of catheter-associated bloodstream infection after introduction of minocycline and rifampin antimicrobial-coated catheters in a pediatric burn population. J Burn Case Res. 2012;33(4):539-543. https://www.ncbi.nlm.nih.gov/pubmed/22210071
  37. Darouiche RO, Berger DH, Khardori N, et al. Comparison of antimicrobial impregnation with tunneling of long-term central venous catheters: a randomized controlled trial. Ann Surg. 2005;242(2):193-200. ncbi.nlm.nih.gov/pmc/articles/PMC1357724/
  38. Hanna H, Benjamin R, Chatzinikolaou I, et al. Long-term silicone central venous catheters impregnated with minocycline and rifampin decrease rates of catheter-related bloodstream infection in cancer patients: a prospective randomized clinical trial. J Clin Oncol. 2004;22(15):3163-3171. ncbi.nlm.nih.gov/pubmed/15284269